We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
A 13-year-old neutered male Maltese dog was presented for hematuria. Survey radiographs were within normal limits. Abnormalities on serum biochemistry included elevated ALP activity and cPL (321).
A 13-year-old neutered male Maltese dog was presented for hematuria. Survey radiographs were within normal limits. Abnormalities on serum biochemistry included elevated ALP activity and cPL (321).
Prostatic mass with cystic portions. This mass appears to invade and destroy the prostatic urethra with expansive mineralizing neoplastic tissue.
The prostate in this patient presented a mineralizing mass that measured 3.21 x 2.25 cm with sublumbar lymphadenopathy that measured 2 x 1.5 cm. There was a pericapsular inflammatory pattern. The prostatic mass demonstrated polypoid proliferation into the cystourethral junction as well. Cystic portions of the prostatic mass were also noted; this may represent dramatically proliferative tissue.
Urinary bladder debris was noted. The bladder wall was unremarkable other than the polypoid changes at the cystourethral junction.
None
Potential drainage of the cystic regions of the prostate can be considered to provide palliative treatment. Stent placement is a possibility in this case. Deramaxx and Enrofloxacin are recommended in the meantime.
Lower urinary tract disease – chronic bacterial cystitis, neoplasia, uroliths, granulomatous cystitis, polyploid cystitis. Prostatic disease – neoplasia, abscess. Upper urinary tract disease – neoplasia, renolith, pyelonephritis.
Increased ALP – hepatic neoplasia, nodular regeneration, Cushing’s disease, disease of the gall bladder (cholecystitis, mucocele), pancreatic/duodenal disease.
Ultrasound-guided FNAs of the prostate and lymph nodes revealed transitional cell carcinoma.
